JP2011006431A5 - - Google Patents

Download PDF

Info

Publication number
JP2011006431A5
JP2011006431A5 JP2010177518A JP2010177518A JP2011006431A5 JP 2011006431 A5 JP2011006431 A5 JP 2011006431A5 JP 2010177518 A JP2010177518 A JP 2010177518A JP 2010177518 A JP2010177518 A JP 2010177518A JP 2011006431 A5 JP2011006431 A5 JP 2011006431A5
Authority
JP
Japan
Prior art keywords
ataxia
adenosine
medicament
prevention
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010177518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011006431A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011006431A publication Critical patent/JP2011006431A/ja
Publication of JP2011006431A5 publication Critical patent/JP2011006431A5/ja
Pending legal-status Critical Current

Links

JP2010177518A 2002-12-19 2010-08-06 アデノシンＡ２ａレセプターアンタゴニストの使用 Pending JP2011006431A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43532102P 2002-12-19 2002-12-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005510511A Division JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013013961A Division JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Publications (2)

Publication Number Publication Date
JP2011006431A JP2011006431A (ja) 2011-01-13
JP2011006431A5 true JP2011006431A5 (enExample) 2011-09-15

Family

ID=34572685

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2005510511A Withdrawn JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用
JP2010177518A Pending JP2011006431A (ja) 2002-12-19 2010-08-06 アデノシンＡ２ａレセプターアンタゴニストの使用
JP2013013961A Withdrawn JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2005510511A Withdrawn JP2006514697A (ja) 2002-12-19 2003-12-17 アデノシンＡ２ａレセプターアンタゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013013961A Withdrawn JP2013136592A (ja) 2002-12-19 2013-01-29 アデノシンＡ２ａレセプターアンタゴニストの使用

Country Status (15)

Country Link
US (2) US7414058B2 (enExample)
EP (3) EP1578409B1 (enExample)
JP (3) JP2006514697A (enExample)
CN (2) CN100415217C (enExample)
AT (1) ATE490775T1 (enExample)
AU (2) AU2003304527B2 (enExample)
BR (1) BR0317436A (enExample)
DE (1) DE60335294D1 (enExample)
ES (1) ES2354875T3 (enExample)
MX (1) MXPA05006790A (enExample)
NO (1) NO20053509L (enExample)
NZ (1) NZ540493A (enExample)
TW (1) TWI331036B (enExample)
WO (1) WO2005044245A1 (enExample)
ZA (1) ZA200504478B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1283839E (pt) * 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20060106040A1 (en) * 2002-12-19 2006-05-18 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
ATE461932T1 (de) * 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
WO2006032273A1 (en) 2004-09-22 2006-03-30 H. Lundbeck A/S 2-acylaminothiazole derivatives
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US7674912B2 (en) * 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
JPWO2006132275A1 (ja) * 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
AR057817A1 (es) * 2005-09-19 2007-12-19 Schering Corp Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
TWI473614B (zh) * 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
BRPI1009398A2 (pt) 2009-03-13 2016-03-08 Advinus Therapeutics Private Ltd compostos de pirimidina fundida substituída
EP2499142B1 (en) 2009-11-09 2016-09-21 Advinus Therapeutics Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
WO2011060207A1 (en) 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
US8473582B2 (en) * 2009-12-16 2013-06-25 International Business Machines Corporation Disconnected file operations in a scalable multi-node file system cache for a remote cluster file system
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
CN103261202B (zh) * 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2014101113A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US11246871B2 (en) 2016-07-15 2022-02-15 Northwestern University Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
AU2018294557A1 (en) * 2017-06-30 2020-01-02 Ryvu Therapeutics S.A. Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor
AU2018389313B2 (en) 2017-12-19 2021-08-19 Impetis Biosciences Ltd. Pharmaceutical composition for the treatment of cancer
AU2019205661B2 (en) 2018-01-04 2022-06-30 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
DE102019116986A1 (de) 2019-06-24 2020-12-24 Helmholtz-Zentrum Dresden-Rossendorf E. V. Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate
WO2021011670A1 (en) * 2019-07-17 2021-01-21 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists and uses thereof
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
US5933964A (en) * 1996-07-17 1999-08-10 Wahl Clipper Corporation Cutter blade for hair clippers
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9915437D0 (en) * 1999-07-01 1999-09-01 Cerebrus Ltd Chemical compounds III
PT1283839E (pt) * 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
ATE424194T1 (de) 2001-04-09 2009-03-15 Neurosearch As Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
AU2002346503A1 (en) 2001-11-30 2003-06-17 Schering Corporation Adenosine A2a receptor antagonists
CA2468658C (en) 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento
ATE400275T1 (de) * 2002-08-30 2008-07-15 Kyowa Hakko Kogyo Kk Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Similar Documents

Publication Publication Date Title
HUS2200018I1 (hu) Drospirenont tartalmazó gyógyszerkészítmény, fogamzásgátlóként történõ alkalmazásra
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
LT3632919T (lt) Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuoto receptoriaus 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
DK2877574T3 (da) Alpha (1,2)-fucosyltransferaser egnet til anvendelse i fremstillingen af fucosylerede oligosaccharider
FR2962442B1 (fr) Composition stable de 2,3,3,3-tetrafluoropropene
CO6791606A2 (es) Composiciones y métodos para el tratamiento en aplicaciones clínicas de amplio espectro, no diferenciadas o combinadas
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
ITMI20111404A1 (it) Supporto per articolazioni umane.
EP2647381A4 (en) MELTING TABLET
EP3068442A4 (en) Bionanofluid for use as a contrast, imaging, disinfecting and/or therapeutic agent
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
SI2739615T1 (sl) Fenil-3-aza-biciklo(3.1.0)heks-3-il-metanoni in njihova uporaba kot zdravilo
IT1403847B1 (it) Composizioni farmaceutiche comprendenti rifaximina e loro uso.
EP3038466A4 (en) 2,2-difluorodioxolo a2a receptor antagonists
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
HRP20260138T1 (hr) Postupak priprave 2,3,3,3-tetrafluoropropena
PL2623499T3 (pl) Pochodne 1,2,4-triazolonu
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112012021455A2 (pt) formulação farmacêutica ou nutracêutica.
BR112014001425A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo
EP2612657A4 (en) MELTING TABLET
ITMI20072141A1 (it) Procedimento per la preparazione del drospirenone